Eosinophilic gastroenteritis: An unclear etiology of ascites and dramatic response to steroids can be a diagnostic key



    Table of Contents     CASE REPORT Year : 2021  |  Volume : 12  |  Issue : 4  |  Page : 183-185  

Eosinophilic gastroenteritis: An unclear etiology of ascites and dramatic response to steroids can be a diagnostic key

Ankit Bhardwaj1, Shoma Mukherjee2
1 Department of Pharmacology, ABVIMS and Dr. RML Hospital, New Delhi, India
2 Department of Pharmacology, School of Medical Sciences & Research, Sharda University, Greater Noida, Uttar Pradesh, New Delhi, India

Date of Submission10-Aug-2021Date of Decision06-Oct-2021Date of Acceptance29-Oct-2021Date of Web Publication09-Feb-2022

Correspondence Address:
Ankit Bhardwaj
Department of Pharmacology, ABVIMS and Dr. RML Hospital, New Delhi - 110 001
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Crossref citationsCheck

DOI: 10.4103/jpp.jpp_104_21

Rights and Permissions

     Abstract 


Eosinophilic gastroenteritis disorder is an uncommon inflammatory disorder of the gastrointestinal tract, affecting predominantly, stomach and small intestine. Subserosal inflammation is a major source of minor-to-moderate ascites. We present the case of an 8-year-old girl child who was brought to the hospital with complaints of chronic abdomen pain and mild ascites. There was a remarkable finding of eosinophils in ascitic fluid. Other differential diagnosis was excluded. Treatment abdomen with deflazacort gave significant resolution of symptoms over the time.

Keywords: Ascites, eosinophilic gastroenteritis, gastrointestinal inflammatory disorder


How to cite this article:
Bhardwaj A, Mukherjee S. Eosinophilic gastroenteritis: An unclear etiology of ascites and dramatic response to steroids can be a diagnostic key. J Pharmacol Pharmacother 2021;12:183-5
How to cite this URL:
Bhardwaj A, Mukherjee S. Eosinophilic gastroenteritis: An unclear etiology of ascites and dramatic response to steroids can be a diagnostic key. J Pharmacol Pharmacother [serial online] 2021 [cited 2022 Feb 9];12:183-5. Available from: 
http://www.jpharmacol.com/text.asp?2021/12/4/183/337449    Introduction Top

Eosinophilic gastroenteritis is a rare pathology, with a prevalence of 28/100,000 population.[1] It is characterized by eosinophilic infiltration of various layers of the gastrointestinal (GI) tract. The clinical presentation is vague and can mimic a variety of GI disorders. Eosinophilic gastroenteritis may affect any segment of gastrointestinal track. Activated eosinophils once recruited, induce significant inflammatory response by secreting cytotoxic granules leading to structural damage and infiltration to intestinal layers.[2]Ascites is a late manifestation of eosinophilic gastroenteritis and occur when the serosal layer of the bowel is affected.[3] Atopy and food allergies are noted in 50%–70% of the cases.[4] We are reporting a case of eosinophilic ascites, which responded dramatically to steroids, in a patient without any history of seasonal and food allergies or asthma. An informed consent for the same has been obtained.

   Case Report Top

We report the case of an 8-year-old girl child with a history of on and off episodes of stomach pain which increased with defecation from the past 2 years. There was a positive history of intermittent on and off alternate episodes of constipation and free motion. Mother denied any positive history of nausea, vomiting, chest pain, shortness of breath, asthma, joint swelling and pores, skin rash, allergic reactions to meals or medications. There was no history of recent travel.

On physical examination, there was no abdominal distension. Bowel sounds were normal, and no diffuse or rebound tenderness was present. On palpation, there were no hepatomegaly/splenomegaly or stomach masses.

[Figure 1]: Ultrasonography shows mild ascites. Abdominal and pelvic magnetic resonance imaging confirmed mild ascites with a thickening of the gastric antrum and proximal small bowel with no mesenteric lymphadenopathy [Figure 2]. No endoparasites seen. An ultrasound-guided ascitic tap was done and fluid sent for routine, microscopy, and adenosine deaminase (ADA) test. The ADA was negative. Ascitic fluid analysis showed 5,600/μL of WBC count with 46% eosinophils. Liver function tests were within described normal range. Serum Immunoglobulin E (IgE) level was 440 IU/mL (accepted upper limit 150 IU/mL). Esophagogastroduodenoscopy, was suggestive of sessile polyp in pre-pyloric region. The rest of the study was normal [Figure 3].

Figure 1: Ultrasonographic demonstration of free peritoneal fluid (arrow)

Click here to view

Figure 2: Confirmation of free peritoneal fluid on contrast-enhanced magnetic resonance imaging (arrow)

Click here to view

Figure 3: Esophagogastroduodenoscopy, (a) normal studies till gastroesophageal junction (b) normal duodenum, (c) sessile polyp in prepyloric region, and (d) normal duodenal bulb

Click here to view

Fecal sample was free of any occult blood, mucous, or endoparasites. The patient was treated with deflazacort (15 mg/day), along with probiotics which was gradually decreased over time and then stopped. Pain abdomen and ascites resolved, and there was decrease in an absolute eosinophil count (106/μL) in peripheral blood. Serum levels of IgE dropped to 76IU/mL; ultrasonography of the abdomen and pelvis confirmed resolving of ascites and small bowel thickening. The patient has been asymptomatic since the past 6 months and is off medications. No signs of stunted growth (based on age vs. weight and height) seen in patient (z score– 1standard deviation).

   Discussion Top

Eosinophilic gastrointestinal disorder (EGID) is a rare disorder, which can present with various GI manifestations depending on the involvement of specific site (esophagus to the rectum) and the layer of the GI tract. Nonspecific GI signs can be present with or without association of peripheral eosinophilia.[3],[4] Grouping of Klein's classification for EGID is primarily based on the GI layer involved., It describes three subtypes of EGID (mucosal, muscular, and subserosal), with an overlap in a few patients.[5],[6]

EGID can occur in a wide age range, from infancy through the seventh decade of life. Although cases have been reported worldwide, the data for the exact incidence of eosinophilic gastroenteritis are inadequate, especially with reference to the genuine occurrence, diagnostic standards, and its subtypes. A total of 10 cases have been reported over a 10-year period in India.[7]

GI signs, laboratory, and pathological findings remain the most common and the most handy diagnostic tool.[7],[8],[9]An increased peripheral count of eosinophils, abundance of eosinophils in the ascitic tap, and the dramatic response to steroids clinches towards the diagnosis and hypersensitivity-mediated pathology of disease.[10]A study by Mayo Clinics reported that more than 50% patients of eosinophilic gastroenteritis had positive history of allergies such as rhinitis, drug allergy, eczema, and asthma, but this case had no such history.[10]

Subserosal inflammation is a source of ascites in EGID.[5],[6] Furthermore, this subgroup of patients are clinically distinct, with stomach bloating (does not get relief with proton-pump inhibitor), better eosinophil counts, and dramatic response to steroid therapy.[4] Untreated patients can remit spontaneously or have extreme malabsorption, ascites and intestinal obstruction. In majority of cases, the disorder is basically benign and pharmacological treatments are not usually indicated.[2]Many patients were reported to get better spontaneously within a couple of days. Dietary control is quite effective in preventing remission of symptoms in about 87.2% of kids and 88% of adults. Corticosteroids are the first line of treatment in most of the patients. A 2-week high-dose steroid therapy was found to provide a dramatic symptomatic relief, no matter what the histological subtype of EGID was. Tapering dose every other 2 weeks is enough to prevent the remission. Relapse might occur only in few cases after months or years of steroid therapy, but repeat therapy promises relief from symptoms. Only a minority of patients require long-term therapy with low dose of deflazacort (6 mg/day). Inpatients who are resistant to corticosteroids, therapy with azathioprine or 6-mercaptopurine must be considered. Humanized anti-interleukin-5 antibodies are a promising and proven therapy; however, unacceptable adverse effects and exorbitant price limits its clinical utility.[5],[10] Nonspecific clinical signs and doubtful etiology of ascites makes this situation ambiguous and liable to misdiagnosis. Only an excellent clinical correlation with laboratory and histopathological findings can unveil the prognosis of this rare, effortlessly treatable disorder. Therapy with low-dose deflazacort may lessen the length and severity of clinical signs and symptoms. Infections with parasites and malignancy must be ruled out before initiating steroid therapy as they can mask the clinical signs for long.

   Conclusion Top

EGID is a rare but curable disorder which mimics many other GI disorders, the diagnosis of which is based on a combination of clinical signs and symptoms along with laboratory, radiological and histopathological findings. Eosinophilic ascites is a rare presentation of EGID, particularly involving the serosal GI tract. The present case was characterized by an obscure etiology of ascites, inflammation of the GI tract, atypical symptoms of on and off episode of constipation, and loose motion and noticeable response to steroid therapy. The present case report might not fill the gap of knowledge on eosinophilic gastroenteritis but will certainly add value to the limited literature available.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 

   References Top
1.Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: Estimates from a national administrative database.J Pediatr Gastroenterol Nutr2016;62:36-42.  Back to cited text no. 1
    2.Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID).J Allergy Clin Immunol2004;113:11-28.  Back to cited text no. 2
    3.Cuko L, Bilaj F, Bega B, Barbullushi A, Resuli B. Eosinophilic ascites, as a rare presentation of eosinophilic gastroenteritis.Hippokratia2014;18:275-7.  Back to cited text no. 3
    4.Agostino A, Parenzi A. Eosinophilic gastroenteritis. A case with predominant involvement of mucosal and muscular layers.Minerva Med1994;85:655-8.  Back to cited text no. 4
    5.Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis.Medicine (Baltimore) 1970;49:299-319.  Back to cited text no. 5
    6.Durieu I, Nove-Josserand R, Cathebras P, Durand DV, RoussetH, Levrat R. Eosinophilic ascites. 2 new case reports.Rev Med Interne1992;13:446-8.  Back to cited text no. 6
    7.Chen MJ, Chu CH, Lin SC, Shih SC, Wang TE. Eosinophilic gastroenteritis: Clinical experience with 15 patients.World J Gastroenterol2003;9:2813-6.  Back to cited text no. 7
    8.Wächter B, Jäger-Arand E, Engers R, Meyerzum Büschenfelde KH, MannsM. Eosinophilic gastroenteritis with serosa involvement. A rare differential diagnosis of ascites.Z Gastroenterol1992;30:469-72.  Back to cited text no. 8
    9.López-Medina G, Gallo M, Prado A, Vicuña-Honorato I, CastilloDíaz de León R. Eosinophilic gastroenteritis: Case report and review in search for diagnostic key points.Case Rep Gastrointest Med2015;2015:239506.  Back to cited text no. 9
    10.Ingle SB, HingeIngle CR. Eosinophilic gastroenteritis: An unusual type of gastroenteritis.World J Gastroenterol2013;19:5061-6.  Back to cited text no. 10
    
  [Figure 1], [Figure 2], [Figure 3]
  Top Print this article  Email this article  

留言 (0)

沒有登入
gif